Occurrence, progression and risk factors of macular atrophy in neovascular age‐related macular degeneration according to neovascularization subtypes
Acta Ophthalmologica · 05.11.2026
DOI: 10.1111/aos.70263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 05.11.2026. Verfasst von Amandine Moulin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Department, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To assess the occurrence, risk factors, and progression of macular atrophy (MA) according to macular neovascularization (MNV) subtype in neovascular AMD (nAMD).
Methods
This multicentre retrospective observational cohort study included 416 eyes with nAMD, followed for at least 12 months and treated with anti‐VEGF. MA was measured annually on near‐infrared imaging. Occurrence and risk factors were analysed by MNV subtype using Kaplan–Meier survival and Cox regression models. Atrophy enlargement rate was assessed in mm 2 /year and after applying square root transformation. MNV subtypes were divided into subepithelial (Type 1), intraretinal (Type 3) and MNV with subretinal component (Type 2 and mixed Type 1+2).
Results
Over a mean follow‐up of 55.4 ± 22.9 months, 47.4% of eyes developed or presented with MA, with the highest prevalence in Type 3 MNV (82%). Kaplan–Meier analysis confirmed a significantly greater risk in Type 3 lesions ( p < 0.0001). Independent risk factors included Type 3 MNV, subretinal drusenoid deposits, thinner choroid and fewer visits with subretinal fluid. After multivariable adjustment, the cumulative number of anti‐VEGF injections was not significantly associated with MA occurrence. The mean MA enlargement rate was 1.0 ± 1.1 mm 2 /year overall, ranging from 0.9 ± 1.1 mm 2 /year in Types 1 to 1.5 ± 1.1 mm 2 /year in MNV with subretinal component, p = 0.002.
Conclusions
Type 3 MNV carries the highest risk of MA, underscoring the need for careful monitoring, whereas MA progression was faster in lesions with a subretinal component. No independent association between cumulative anti‐VEGF injection number and MA occurrence was observed; however, this finding should be interpreted cautiously given the potential for confounding by disease activity, MNV subtype, treatment regimen and follow‐up intensity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Ophthalmology Department, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France.
- Ophthalmology Department, Aix-Marseille University, North Hospital, Marseille, France.
- Monticelli Paradis Center, Marseille, France.
- Almaviva Health Group, Juge Clinic, Marseille, France.
- Ophthalmology Department, Valence Hospital Center, Valence, France.
- LEO Eye Center, Private Hospital of East Lyon, Saint-Priest, France.
ORCID-Profile: Benjamin Wolff, Pierre Pradat, Laurent Kodjikian, Thibaud Mathis
Zitieren
APA
Moulin, A., Zeender, G., Rizzuto, P., Gascon, P., Allaix, K., Feldman, A., De Bats, F., Wolff, B., Pradat, P., Desmangles, P., Kodjikian, L., & Mathis, T. (2026). Occurrence, progression and risk factors of macular atrophy in neovascular age‐related macular degeneration according to neovascularization subtypes. Acta Ophthalmologica. https://doi.org/10.1111/aos.70263
Vancouver
Moulin A, Zeender G, Rizzuto P, Gascon P, Allaix K, Feldman A, et al. Occurrence, progression and risk factors of macular atrophy in neovascular age‐related macular degeneration according to neovascularization subtypes. Acta Ophthalmologica. 2026. doi:10.1111/aos.70263
BibTeX
@article{Moulin2026,
author = {Moulin, Amandine and Zeender, Geoffrey and Rizzuto, Pauline and Gascon, Pierre and Allaix, Kevin and Feldman, Audrey and De Bats, Flore and Wolff, Benjamin and Pradat, Pierre and Desmangles, Philippe and Kodjikian, Laurent and Mathis, Thibaud},
title = {Occurrence, progression and risk factors of macular atrophy in neovascular age‐related macular degeneration according to neovascularization subtypes},
journal = {Acta Ophthalmologica},
year = {2026},
doi = {10.1111/aos.70263}
}
EUVIMED